LONDON — China’s biotech sector is steadily moving beyond a “me-too” approach to drug development thanks to a surge in quality talent, regulatory flexibility and a level of speed that’s tough to rival, industry executives said …
Novo’s double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
→ A decorated GLP-1 pioneer is retiring at Novo Nordisk. Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on

